1-(4-溴苯基)-4-氯-1H-吡唑并[3,4-d]嘧啶 | 832715-52-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-(4-溴苯基)-4-氯-1H-吡唑并[3,4-d]嘧啶
• 中文别名: 1-(4-溴苯基)-4-氯-1H-吡唑[3,4-D]嘧啶
• 英文名称: 1-(4-bromophenyl)-4-chloro-1H-pyrazolo[3,4-d]pyrimidine
• 英文别名: 1-(4-bromophenyl)-4-chloropyrazolo[3,4-d]pyrimidine
• CAS: 832715-52-3
• 化学式: C₁₁H₆BrClN₄
• mdl: MFCD11104746
• 分子量: 309.552
• InChiKey: UZYNDGAOOONELP-UHFFFAOYSA-N

物化性质

• 沸点：
  365.5±42.0 °C(Predicted)
• 密度：
  1.81±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

SDS

1-(4-溴苯基)-4-氯-1H-吡唑并[3,4-d]嘧啶MSDS英文版

反应信息

• 作为反应物：
  描述：

  1-(4-溴苯基)-4-氯-1H-吡唑并[3,4-d]嘧啶 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 1.5h， 以81%的产率得到4-[1-(4-bromo-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yloxy]-piperidine-1-carboxylic acid isopropyl ester
  参考文献：
  名称：

  [EN] FUSED-ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF METABOLISM AND THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO
  [FR] DERIVES ARYLE ET HETEROARYLE CONDENSES UTILISES COMME MODULATEURS DU METABOLISME ET PROPHYLAXIE ET TRAITEMENT DES TROUBLES METABOLIQUES

  摘要：

  公开号：

  WO2005007658A3
• 作为产物：
  描述：

  1-(4-溴-苯基)-1,5-二氢-吡唑并[3,4-d]嘧啶-4-酮 在 三氯氧磷 作用下， 反应 12.0h， 生成 1-(4-溴苯基)-4-氯-1H-吡唑并[3,4-d]嘧啶
  参考文献：
  名称：

  吡唑并[3,4-d]嘧啶的设计与合成：释放针对肝细胞癌的一氧化氮释放化合物。

  摘要：

  设计并合成了一系列新的与一氧化氮（NO）连接的吡唑并[3,4-d]嘧啶类化合物。Sulforhodamine B（SRB）蛋白测定表明，合成的化合物中的NO释放部分比des-NO类似物明显减少了细胞生长。具有N-对位取代苯基的化合物7C和7G释放的最高NO浓度分别为4.6％和4.7％。与厄洛替尼作为参考药物（IC50）相比，合成化合物对HepG2细胞系的抗增殖活性分别将化合物7h，7p，14a和14b鉴定为IC50 = 3、5、3和5μM系列中最具细胞毒性的化合物。 =25μM）。流式细胞仪研究表明，7h使细胞处于细胞周期的G0 / G1期，而7p使细胞处于S期。而且，

  DOI：

  10.1016/j.bmc.2017.03.002

文献信息

• N–N Bond-Forming Cyclization for the One-Pot Synthesis of <i>N</i>-Aryl[3,4-<i>d</i>]pyrazolopyrimidines
  作者：Lindsay E. Evans、Matthew D. Cheeseman、Keith Jones

  DOI：10.1021/ol301561a

  日期：2012.7.6

  An efficient one-pot synthesis of N-aryl[3,4-d]pyrazolopyrimidines in good yield and under mild reaction conditions is described. By exploiting electron-deficient hydroxylamines, the substituted oxime products were formed with very high E-diastereoselectivity. The key step utilizes a cyclization reaction upon an oxime derived from hydroxylamine-O-sulfonic acid to form the N–N bond of the product.

  描述了N-芳基[3,4- d ] 吡唑并嘧啶的高效一锅法合成，收率良好，反应条件温和。通过利用缺电子羟胺，形成了具有非常高的E-非对映选择性的取代肟产物。关键步骤是利用羟胺-O-磺酸衍生的肟进行环化反应，形成产物的 N-N 键。
• [EN] PYRAZOLOPYRIMIDINES AS ANTI - HEPATITS C AGENTS<br/>[FR] PYRAZOLOPYRIMIDINES UTILISES COMME AGENTS ANTI-HEPATITE C
  申请人：ARROW THERAPEUTICS LTD

  公开号：WO2005047288A1

  公开（公告）日：2005-05-26

  Pyrazolopyrimidine derivatives of formula (I), or a pharmaceutically acceptable salt thereof, are found to be active against hepatitis C infection, wherein: R1 is C6-C10 aryl, 5- to 10- membered heteroary1, -(C1-C4 alkyl)-(C6-C10 aryl) or -(C1-C4 alkyl)-(5- to 10- membered heteroaryl); R2 is a C6-C10 aryl, C3-C6 carbocyclyl, 5- to 10- membered heteroaryl or 5- to 10- membered heterocyclyl moiety, said moiety being optionally fused to a C6­C10 aryl, C3-C6 carbocyclyl, 5- to 10- membered heteroaryl or 5- to 10­membered heterocyclic ring; and X is -NR'-, -NR'-CO-NR''-, -NR'-L, or -NR'-CO-L-, wherein R' and R'' are the same or different and each represent hydrogen or a C1-C6 alkyl group and L represents a C1-C6 alkylene group, the aryl, heteroaryl, heterocyclyl. and carbocyclyl moieties in the R1 and R2 substituents being unsubstituted or substituted by 1, 2 or 3 substituents selected from halogen, C1-C4 alkyl C1-C4alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, cyano, nitro, C6-C10 aryl, C3-C6 carbocyclyl, 5- to 10- membered heterocyclyl, 5- to 10- membered heteroaryl, -NR'­CO2-R'', -CO2R'', -COR'''-NR'-CO-R''',-CONR'R'',SO2NR'R'',SO2R'''and -O-(CH2)n-R''' substituents, wherein n is from 0 to 4, each R’is the same or different and is hydrogen or C1-C6 alkyl, each R'' is the same or different and is hydrogen, C1-C6 alkyl, C6-C10 aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heteroaryl, each R''' is the same or different and is C1-C6 alkyl, C6-C10 aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heteroaryl, and each R'''' is the same or different and is C6-C10 aryl, 5- to 10- membered heterocyclyl or 5- to 10- membered heterocryl, the aryl, heteroaryl, heterocyclyl and carbocyclyl moieties in said substituents being unsubstituted or substituted by a further substituent selected from C1-C4 alkyl, C1-C4 hydroxyalkyl and C1-C4 haloalkyl groups.

  式(I)的吡唑啉衍生物，或其药用可接受的盐，被发现对丙型肝炎感染具有活性，其中：R1为C6-C10芳基，5-到10-成员杂芳基，-(C1-C4烷基)-(C6-C10芳基)或-(C1-C4烷基)-(5-到10-成员杂芳基)；R2为C6-C10芳基，C3-C6碳环烷基，5-到10-成员杂芳基或5-到10-成员杂环烷基基团，该基团可选择地与C6-C10芳基，C3-C6碳环烷基，5-到10-成员杂芳基或5-到10-成员杂环烷基环融合；X为-NR'-，-NR'-CO-NR''-，-NR'-L，或-NR'-CO-L-，其中R'和R''相同或不同，分别代表氢或C1-C6烷基，L代表C1-C6烷基基团，R1和R2取代基中的芳基，杂芳基，杂环烷基和碳环烷基基团未取代或通过1、2或3个卤素、C1-C4烷基、C1-C4烷氧基、C1-C4卤代烷基、C1-C4卤代烷氧基、氰基、硝基、C6-C10芳基、C3-C6碳环烷基、5-到10-成员杂环烷基、5-到10-成员杂芳基、-NR'-CO2-R''、-CO2R''、-COR'''-NR'-CO-R'''、-CONR'R''、SO2NR'R''、SO2R'''和-O-(CH2)n-R'''取代。
• Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
  申请人：Jones M. Robert

  公开号：US20060142262A1

  公开（公告）日：2006-06-29

  The present invention relates to certain fused aryl and heteroaryl derivatives of Formula (I) that are modulators of metabolism. Accordingly, compounds of the present invention are useful in the prophylaxis or treatment of metabolic disorders and complications thereof, such as, diabetes and obesity.

  本发明涉及公式（I）的某些融合芳基和杂芳基衍生物，它们是代谢调节剂。因此，本发明的化合物在预防或治疗代谢性疾病及其并发症方面非常有用，如糖尿病和肥胖症。
• 1,4 Substituted Pyrazolopyrimidines as Kinase Inhibitors
  申请人：Schmiedeberg Niko

  公开号：US20080096868A1

  公开（公告）日：2008-04-24

  The invention relates to 1,4-substituted pyrazolopyrimidine compounds of the formula I, pharmaceuticals comprising a 1,4-substituted pyrazolopyrimidine compound, the use of a 1,4-substituted pyrazolopyrimidine compound in the treatment or the use thereof in the manufacture of a pharmaceutical formulation for the treatment of a disease that depends on inadequate activity of a protein kinase, methods of treatment comprising administering a 1,4-substituted pyrazolopyrimidine compound, methods for the manufacture of a novel compound of that class, and novel intermediates and partial steps for their synthesis.

  本发明涉及公式I的1,4-取代嘧唑嘧啶化合物，包括一种含有1,4-取代嘧唑嘧啶化合物的药物，使用1,4-取代嘧唑嘧啶化合物治疗或用其制造药物配方以治疗依赖于蛋白激酶不足活性的疾病，包括给予1,4-取代嘧唑嘧啶化合物的治疗方法，制造该类新化合物的方法，以及其合成的新中间体和部分步骤。
• 3-(Substituted Amino)-Pyrazolo[3, 4-D]Pyrimidines as Ephb and Vegfr2 Kinase Inhibitors
  申请人：Holzer Philipp

  公开号：US20080275054A1

  公开（公告）日：2008-11-06

  The invention relates to novel pyrazolo[3,4-d]pyrimidines of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their use as medicaments and to medicaments comprising them.

  本发明涉及一种新的吡唑并[3,4-d]嘧啶化合物，其化学式为，在该式中，所有变量均如规范中定义的那样，以自由形式或盐形式存在，以及其制备方法，其作为药物的用途以及包含它们的药物。